NVS Stock Analysis & IQ Rating | Novartis AG

Chart

Interim Report for the period July - September 2025: BioArctic. Broadening our portfolio with new projects and partnerships Events during the third quarter 2025New data on lecanemab were presented at the AAIC-congress focused on long-term efficacy and safety real world evidence and subcutaneous dosingOption collaboration and license agreement signed with Novartis with an upfront payment of US FDA approved weekly subcutaneous maintenance treatment with Leqembi®. Iqlik™. for the treatmen

Today

Novartis AG Basel Reaches Analyst Target Price. In recent trading shares of Novartis AG Basel (Symbol: NVS) have crossed above the average analyst 12-month target price of $127.00 changing hands for $127.11/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react: downgrade on v

Tue Nov 11, 2025

Food Allergy Market Valued at USD 3 Billion across the 7MM Projected to Grow at CAGR of 11.3% by 2034 | DelveInsight. Food Allergy Market Valued at USD 3 Billion across the 7MM Projected to Grow at CAGR of 11.3% by 2034 |. DelveInsightThe food allergy market is expected to surge in the coming years primarily due to the adoption of recently approved therapies potential emerging therapies such as Viaskin (DBV712) Peanut Patch (DBV Technologies) PVX108 (Aravax) Remibrutinib (Novartis) SLIT tabl

Mon Nov 10, 2025

Novartis launches new manufacturing facility in California.

Mon Nov 10, 2025

LNTH: Can AD Franchise Offset Pylarify Drag?. By Lantheus Holdings Inc. (NASDAQ:LNTH) reported third quarter 2025 financial and operational results on November 6th producing sales of $384 million a 1% increase compared to 3Q:24 levels. Pylarify and Strategic Partnerships saw a year over year decline which was offset by an increase in revenue from Definity TechneLite and Other Precision Diagnostics sales. NeuraCeq revenues were recognized for the first time in 3Q:25 adding $20 million in sales. F

Mon Nov 10, 2025

Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan.

Mon Nov 10, 2025

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger. We recently published 10 Stocks With Easy 20-40% Gains. Avidity Biosciences Inc. (NASDAQ:RNA) is one of the last week’.s best-performing stocks. Avidity Biosciences climbed by 42.1 percent week-on-week as investors gobbled up shares after confirming a $12 billion merger plan with Novartis AG. Earlier in the week Novartis said it entered into an agreement with [….]

Mon Nov 3, 2025

Is the Market ish or Bearish on Novartis AG?. NVS) short interest as a percent of float has fallen 4.35% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if ...

Wed Oct 29, 2025

Novartis AG (NYSE:NVS) Q3 2025 Earnings Call Transcript. Novartis AG (NYSE:NVS) Q3 2025 Earnings Call Transcript October 28 2025 Novartis AG misses on earnings expectations. Reported EPS is $2.25 EPS expectations were $2.26. Operator: Good morning and good afternoon and welcome to the Novartis Q3 2025 Results Release Conference Call and Live Webcast. [Operator Instructions] The conference is being recorded. [Operator Instructions] A [….]

Wed Oct 29, 2025

Novartis Lags Q3 Earnings Announces $12B Avidity Biosciences Acquisition. Novartis Q3 profit rose on 8% higher sales led by Kisqali Kesimpta and Pluvicto as new acquisitions expand its neuroscience and cardiovascular reach.

Tue Oct 28, 2025